Microsatellite instability and 8p allelic imbalance in stage B2 and C colorectal cancers

Journal of the National Cancer Institute

Volumn 91, Issue 15, 1999, Pages 1295-1303

  Halling, Kevin C ^a   French, Amy J ^a   McDonnell, Shannon K ^a   Burgart, Lawrence J ^a   Schaid, Daniel J ^a   Peterson, Brett J ^a   Moon Tasson, Laurie ^a   Mahoney, Michelle R ^a   Sargent, Daniel J ^a   O'Connell, Michael J ^b   Witzig, Thomas E ^a   Farr Jr , Gist H ^b   Goldberg, Richard M ^b   Thibodeau, Stephen N ^a  

^a MAYO CLINIC   (United States)

^b North Central Cancer Treatment Group Rochester   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ALLELE; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CHROMOSOME 17P; CHROMOSOME 18Q; CHROMOSOME 5Q; CHROMOSOME 8P; CHROMOSOME ARM; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE INSTABILITY; MUTATION; PRIORITY JOURNAL; RECURRENT DISEASE;

EID: 0033523204     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/91.15.1295     Document Type: Article

References (78)

1. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics, 1997 [published erratum appears in CA Cancer J Clin 1997;47:68]. CA Cancer J Clin 1997;47:5-27.
2. Vaughn DJ, Haller DG. Adjuvant therapy for colorectal cancer: past accomplishments, future directions. Cancer Invest 1997;15:435-47.
3. O'Connell MJ, Martenson JA, Wieand HS, Krook JE, Macdonald JS, Haller DG, et al. Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med 1994;331:502-7.
4. Manounas EP, Rockette H, Jones J, Wieand HS, Wickerham DL, Fisher B, et al. Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four NSABP adjuvant studies (C-01, C-02, C-03, C-04). J Clin Oncol 1999;17:1349-55.
5. Impact B2 Investigators. Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. J Clin Oncol 1998;17:1356-63.
6. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990;61:759-67.
7. Fearon ER. Molecular genetics of colorectal cancer. Ann N Y Acad Sci 1995;768:101-10.
8. Lengauer C, Kinzler KW, Vogelstein B. Genetic instability in colorectal cancers. Nature 1997;386:623-7.
9. Dutrillaux B. Pathways of chromosome alteration in human epithelial cancers. Adv Cancer Res 1995;67:59-82.
10. Sweezy MA, Fishel R. Multiple pathways leading to genomic instability and tumorigenesis. Ann N Y Acad Sci 1994;726:165-77.
11. Thibodeau SN, Bren G, Schaid D. Microsatellite instability in cancer of the proximal colon. Science 1993;260:816-9.
12. Lothe RA, Peltomaki P, Meling GI, Aaltonen LA, Nystrom-Lahti M, Pylkkanen L, et al. Genomic instability in colorectal cancer: relationship to clinicopathological variables and family history. Cancer Res 1993;53: 5849-52.
13. Laurent-Puig P, Olschwang S, Delattre O, Remvikos Y, Asselain B, Melot T, et al. Survival and acquired genetic alterations in colorectal cancer. Gastroenterology 1992;102:1136-41.
14. Kern SE, Fearon ER, Tersmette KW, Enterline JP, Leppert M, Nakamura Y, et al. Clinical and pathological associations with allelic loss in colorectal carcinoma [corrected] [published erratum appears in JAMA 1989;262: 1952]. JAMA 1989;261:3099-103.
15. Jen J, Kim H, Piantadosi S, Liu ZF, Levitt RC, Sistonen P, et al. Allelic loss of chromosome 18q and prognosis in colorectal cancer. N Engl J Med 1994;331:213-21.
16. Laurie JA, Moertel CG, Fleming TR, Wieand HS, Leigh JE, Rubin J, et al. Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. The North Central Cancer Treatment Group and the Mayo Clinic. J Clin Oncol 1989; 7:1447-56.
17. Beart RW Jr, Moertel CG, Wieand HS, Leigh JE, Windschitl HE, van Heerden JA, et al. Adjuvant therapy for resectable colorectal carcinoma with fluorouracil administered by portal vein infusion. A study of the Mayo Clinic and the North Central Cancer Treatment Group. Arch Surg 1990; 125:897-901.
18. Krook JE, Moertel CG, Gunderson LL, Wieand HS, Collins RT, Beart RW, et al. Effective surgical adjuvant chemotherapy for high-risk rectal carcinoma. N Engl J Med 1991;324:709-15.
19. Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laune JA, Tangen CM, et al. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med 1995;122:321-6.
20. Wiesenfeld M, O'Connell MJ, Wieand HS, Gonchoroff NJ, Donohue JH, Fitzgibbons RJ Jr, et al. Controlled clinical trial of interferon-γ as postoperative surgical adjuvant therapy for colon cancer. J Clin Oncol 1995;13: 2324-9.
21. O'Connell MJ, Laurie JA, Kahn M, Fitzgibbons RJ Jr, Erlichman C, Shepherd L, et al. Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. J Clin Oncol 1998; 16:295-300.
22. Astler VB, Coller J. The prognostic significance of direct extension of carcinoma of the colon and rectum. Ann Surg 1954;139:846-51.
23. Dukes CE. Histological grading of rectal cancer. Proc Royal Soc Med 1937;30:371-6.
24. Jass JR, Atkin WS, Cuzick J, Bussey HJ, Morson BC, Northover JM, et al. The grading of rectal cancer: historical perspectives and a multivariate analysis of 447 cases. Histopathology 1986;10:437-59.
25. Thibodeau SN, French AJ, Cunningham JM, Tester D, Burgart LJ, Roche PC, et al. Microsatellite instability in colorectal cancer: different mutator phenotypes and the principal involvement of hMLH1. Cancer Res 1998; 58:1713-8.
26. Moslein G, Tester DJ, Lindor NM, Honchel R, Cunningham JM, French AJ, et al. Microsatellite instability and mutation analysis of hMSH2 and hMLH1 in patients with sporadic, familial and hereditary colorectal cancer. Hum Mol Genet 1996;5:1245-52.
27. Cunningham JM, Shan A, Wick MJ, McDonnell SK, Schaid DJ, Tester DJ, et al. Allelic imbalance and microsatellite instability in prostatic adenocarcinoma. Cancer Res 1996;56:4475-82.
28. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
29. Cox DR. Regression models and life tables. J R Stat Soc [B] 1972;34: 187-220.
30. Vogelstein B, Fearon ER, Kern SE, Hamilton SR, Preisinger AC, Nakamura Y, et al. Allelotype of colorectal carcinomas. Science 1989;244: 207-11.
31. SAS/STAT user's guide, Version 6. Cary (NC): SAS Institute, Inc.; 1989.
32. Khine K, Goh HS, Smith DR. Prognostic significance of chromosome 5q and 17p deletion in colorectal adenocarcinomas. Int J Oncol 1995;7: 631-5.
33. Campo E, Miquel R, Jares P, Bosch F, Juan M, Leone A, et al. Prognostic significance of the loss of heterozygosity of Nm23-H1 and p53 genes in human colorectal carcinomas. Cancer 1994;73:2913-21.
34. O'Connell MJ, Schaid DJ, Ganju V, Cunningham J, Kovach JS, Thibodeau SN. Current status of adjuvant chemotherapy for colorectal cancer: can molecular markers play a role in predicting prognosis? Cancer 1992;70(6 Suppl):1732-9.
35. Ogunbiyi OA, Goodfellow PJ, Herfarth K, Gagliardi G, Swanson PE, Birnbaum EH, et al. Confirmation that chromosome 18q allelic loss in colon cancer is a prognostic indicator. J Clin Oncol 1998;16:427-33.
36. Martinez-Lopez E, Abad A, Font A, Monzo M, Ojanguren I, Pifarre A, et al. Allelic loss on chromosome 18q as a prognostic marker in stage II colorectal cancer. Gastroenterology 1998;114:1180-7.
37. Carethers JM, Hawn MT, Greenson JK, Hitchcock CL, Boland CR. Prognostic significance of allelic loss at chromosome 18q21 for stage II colorectal cancer. Gastroenterology 1998;114:1188-95.
38. Fujiwara Y, Emi M, Ohata H, Kato Y, Nakajima T, Mori T, et al. Evidence for the presence of two tumor suppressor genes on chromosome 8p for colorectal carcinoma. Cancer Res 1993;53:1172-4.
39. Kelemen PR, Yaremko ML, Kim AH, Montag A, Michelassi F, Westbrook CA. Loss of heterozygosity in 8p is associated with microinvasion in colorectal carcinoma. Genes Chromosomes Cancer 1994;11:195-8.
40. Michelassi F, Vannucci L, Ayala JJ, Chappell R, Goldberg R, Block GE. Local recurrence after curative resection of colorectal adenocarcinoma. Surgery 1990;108:787-92; discussion 792-3.
41. Michelassi F, Ayala JJ, Balestracci T, Goldberg R, Chappell R, Block GE. Verification of a new clinicopathologic staging system for colorectal adenocarcinoma. Ann Surg 1991;214:11-8.
42. Scholnick SB, Haughey BH, Sunwoo JB, el-Mofty SK, Baty JD, Piccirillo JF, et al. Chromosome 8 allelic loss and the outcome of patients with squamous cell carcinoma of the supraglottic larynx. J Natl Cancer Inst 1996;88:1676-82.
43. 0 prostate cancer. Genes Chromosomes Cancer 1998;21: 131-43.
44. Bova GS, Carter BS, Bussemakers MJ, Emi M, Fujiwara Y, Kyprianou N, et al. Homozygous deletion and frequent allelic loss of chromosome 8p22 loci in human prostate cancer. Cancer Res 1993;53:3869-73.
45. Knowles MA, Shaw ME, Proctor AJ. Deletion mapping of chromosome 8 in cancers of the urinary bladder using restriction fragment length polymorphisms and microsatellite polymorphisms. Oncogene 1993;8: 1357-64.
46. Yaremko ML, Wasylyshyn ML, Paulus KL, Michelassi F, Westbrook CA. Deletion mapping reveals two regions of chromosome 8 allele loss in colorectal carcinomas. Genes Chromosomes Cancer 1994;10:1-6.
47. Fujiwara Y, Ohata H, Emi M, Okui K, Koyama K, Tsuchiya E, et al. A 3-Mb physical map of the chromosome region 8p21.3-p22, including a 600-kb region commonly deleted in human hepatocellular carcinoma, colorectal cancer, and non-small cell lung cancer. Genes Chromosomes Cancer 1994;10:7-14.
48. Cunningham C, Dunlop MG, Wyllie AH, Bird CC. Deletion mapping in colorectal cancer of a putative tumour suppressor gene in 8p22-p21.3. Oncogene 1993;8:1391-6.
49. Gustafson CE, Wilson PJ, Lukeis R, Baker E, Woollatt E, Annab L, et al. Functional evidence for a colorectal cancer tumor suppressor gene at chromosome 8p22-23 by monochromosome transfer. Cancer Res 1996;56: 5238-45.
50. Farrington SM, Cunningham C, Boyle SM, Wyllie AH, Dunlop MG. Detailed physical and deletion mapping of 8p with isolation of YAC clones from tumour suppressor loci involved in colorectal cancer. Oncogene 1996; 12:1803-8.
51. Wu CL, Roz L, Sloan P, Read AP, Holland S, Porter S, et al. Deletion mapping defines three discrete areas of allelic imbalance on chromosome arm 8p in oral and oropharyngeal squamous cell carcinomas. Genes Chromosomes Cancer 1997;20:347-533.
52. Cunningham C, Dunlop MG, Bird CC, Wyllie AH. Deletion analysis of chromosome 8p in sporadic colorectal adenomas. Br J Cancer 1994;70: 18-20.
53. Paredes-Zaglul A, Kang JJ, Esiig YP, Mao W, Irby R, Wloch M, et al. Analysis of colorectal cancer by comparative genomic hybridization: evidence for induction of the metastatic phenotype by loss of tumor suppressor genes. Clin Cancer Res 1998;4:879-86.
54. Gerdes H, Chen Q, Elahi AH, Sircar A, Goldberg E, Winawer D, et al. Recurrent deletions involving chromosomes 1, 5, 17, and 18 in colorectal carcinoma: possible role in biological and clinical behavior of tumors. Anticancer Res 1995;15:13-24.
55. Bubb VJ, Curtis LJ, Cunningham C, Dunlop MG, Carothers AD, Morris RG, et al. Microsatellite instability and the role of hMSH2 in sporadic colorectal cancer. Oncogene 1996;12:2641-9.
56. Cawkwell L, Li D, Lewis FA, Martin I, Dixon MF, Quirke P. Microsatellite instability in colorectal cancer: improved assessment using fluorescent polymerase chain reaction. Gastroenterology 1995;109:465-71.
57. Lukish JR, Muro K, DeNobile J, Katz R, Williams J, Cruess DF, et al. Prognostic significance of DNA replication errors in young patients with colorectal cancer. Ann Surg 1998;227:51-6.
58. Lynch HT, Bardawil WA, Harris RE, Lynch PM, Guirgis HA, Lynch JF. Multiple primary cancers and prolonged survival: familial colonie and endometrial cancers. Dis Colon Rectum 1978;21:165-8.
59. Sankila R, Aaltonen LA, Jarvinen HJ, Mecklin JP. Better survival rates in patients with MLH1-associated hereditary colorectal cancer. Gastroenterology 1996;110:682-7.
60. Aaltonen LA, Peltomaki P, Leach FS, Sistonen P, Pylkkanen L, Mecklin JP. et al. Clues to the pathogenesis of familial colorectal cancer. Science 1993;260:812-6.
61. Liu B, Parsons R, Papadopoulos N, Nicolaides NC, Lynch HT, Watson P, et al. Analysis of mismatch repair genes in hereditary nonpolyposis colorectal cancer patients. Nat Med 1996;2:169-74.
62. Kane MF, Loda M, Gaida GM, Lipman J, Mishra R, Goldman H, et al. Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. Cancer Res 1997;57:808-11.
63. Cunningham JM, Christensen ER, Tester DJ, Kim CY, Roche PC, Burgart LJ, et al. Hypermethylation of the hMLH1 promoter in colon cancer with microsatellite instability. Cancer Res 1998;58:3455-60.
64. Herman JG, Umar A, Polyak K, Graff JR, Ahuja N, Issa JP, et al. Incidence and functional consequences of hMLHI promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci U S A 1998;95:6870-5.
65. Veigl ML, Kasturi L, Olechnowicz J, Ma AH, Lutterbaugh JD, Periyasamy S, et al. Biallelic inactivation of hMLHI by epigenetic gene silencing, a novel mechanism causing human MSI cancers. Proc Natl Acad Sci U S A 1998;95:8698-702.
66. Offerhaus GJ, De Feyter EP, Cornelisse CJ, Tersmette KW, Floyd J, Kern SE, et al. The relationship of DNA aneuploidy to molecular genetic alterations in colorectal carcinoma. Gastroenterology 1992;102:1612-9.
67. Dix BR, Robbins P, Soong R, Jenner D, House AK, Iacopetta BJ. The common molecular genetic alterations in Dukes' B and C colorectal carcinomas are not short-term prognostic indicators of survival. Int J Cancer 1994;59:747-51.
68. Riggins GJ, Thiagalingam S, Rozenblum E, Weinstein CL, Kern SE, Hamilton SR, et al. Mad-related genes in the human. Nat Genet 1996;13:347-9.
69. Thiagalingam S, Lengauer C, Leach FS, Schutte M, Hahn SA, Overhauser J, et al. Evaluation of candidate tumour suppressor genes on chromosome 18 in colorectal cancers. Nat Genet 1996;13:343-6.
70. Eppert K, Scherer SW, Ozcelik H, Pirone R, Hoodless P, Kim H, et al. MADR2 maps to 18q21 and encodes a TGF-β-regulated MAD-related protein that is functionally mutated in colorectal carcinoma. Cell 1996;86: 543-52.
71. Baker SJ, Preisinger AC, Jessup JM, Paraskeva C, Markowitz S, Willson JK, et al. p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis. Cancer Res 1990;50:7717-22.
72. Campo E, de la Calle-Martin O, Miquel R, Palacin A, Romero M, Fabregat V, el al. Loss of heterozygosity of p53 gene and p53 protein expression in human colorectal carcinomas. Cancer Res 1991;51:4436-42.
73. Cunningham J, Lust JA, Schaid DJ, Bren GD, Carpenter HA, Rizza E, et al. Expression of p53 and 17p allelic loss in colorectal carcinoma. Cancer Res 1992;52:1974-80.
74. Rodrigues NR, Rowan A, Smith ME, Kerr IB, Bodmer WF, Cannon JV, et al. p53 mutations in colorectal cancer. Proc Natl Acad Sci U S A 1990;87: 7555-9.
75. Smith DR. Goh HS. p53 and prognosis in colorectal cancer. Ann Acad Med Singapore 1996;25:107-12.
76. Goh HS, Yao J, Smith DR. p53 point mutation and survival in colorectal cancer patients. Cancer Res 1995;55:5217-21.
77. Smith DR, Ji CY, Goh HS. Prognostic significance of p53 overexpression and mutation in colorectal adenocarcinomas. Br J Cancer 1996;74:216-23.
78. Hamelin R, Laurent-Puig P, Olschwang S, Jego N, Asselain B, Remvikos Y, et al. Association of p53 mutations with short survival in colorectal cancer. Gaslroenterology 1994;106:42-8.